Dow Up0.11% Nasdaq Up0.50%

Ultragenyx Pharmaceutical Inc. (RARE)

-NasdaqGS
53.36 Down 0.51(0.95%) Aug 29, 4:00PM EDT
|After Hours : 53.37 Up 0.01 (0.01%) Aug 29, 4:45PM EDT
ProfileGet Profile for:
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, CA 94949
United States - Map
Phone: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:88

Business Summary 

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody in Phase 1/2 clinical trial to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy in Phase 1/2 clinical trial for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy in preclinical development for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy in a Phase 2 clinical trial for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid in a Phase 2 extension study to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Ultragenyx Pharmaceutical Inc.

Key Executives 
 PayExercised
Dr. Emil D. Kakkis M.D., Ph.D., 54
Chief Exec. Officer, Pres and Director
466.00K0.00
Ms. Shalini Sharp , 39
Chief Financial Officer and Sr. VP
442.00K0.00
Mr. Thomas R. Kassberg , 54
Chief Bus. Officer and Sr. VP
424.00K0.00
Mr. Theodore A. Huizenga , 43
Principal Accounting Officer and Corp. Controller
N/AN/A
Mr. Michael Vellard Ph.D., 53
VP of Research
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders